Iradimed (NASDAQ:IRMD) Posts Earnings Results, Misses Estimates By $0.05 EPS

Iradimed (NASDAQ:IRMD) announced its earnings results on Thursday. The medical equipment provider reported $0.40 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.05), Zacks reports. Iradimed had a net margin of 26.12% and a return on equity of 23.99%.

Iradimed Price Performance

IRMD stock traded down $6.38 during mid-day trading on Thursday, reaching $54.11. 38,732 shares of the company traded hands, compared to its average volume of 39,580. Iradimed has a 52-week low of $40.18 and a 52-week high of $63.29. The company has a market capitalization of $685.51 million, a P/E ratio of 36.54 and a beta of 0.82. The company has a fifty day moving average price of $57.16 and a 200-day moving average price of $52.02.

Analyst Ratings Changes

Separately, StockNews.com cut Iradimed from a “strong-buy” rating to a “buy” rating in a report on Thursday.

Insider Transactions at Iradimed

In other news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This represents a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 37.10% of the company’s stock.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.